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Maternally Inherited Cardiomyopathy: An Atypical
Presentation of the mtDNA 12S rRNA Gene A1555G
Mutation
To the Editor:
Human mitochondrial disorders comprise a heteroge-
neous group of multisystem diseases, characterized by
morphological, biochemical, or genetic abnormalities of
mitochondria. Mutations in mtDNA have been de-
scribed predominantly in a variety of rare encephalo-
myopathies but are also emerging in association with
more common disorders, such as sensorineural hearing
loss (SNHL) and cardiomyopathies (DiMauro and Bon-
illa 1997). Most of the identified mtDNA mutations are
associated with specific clinical phenotypes (DiMauro
and Bonilla 1997). In a recent issue of the Journal, Es-
tivill et al. (1998) reported that the A1555G mutation
in the mitochondrial 12S rRNA is responsible for a sig-
nificant number of cases of maternally inherited non-
syndromic hearing loss and that its pathogenic role is
enhanced by treatment with aminoglycosides.
Idiopathic cardiomyopathies are an important cause
of morbidity and mortality throughout the world, both
in children and adults, with an annual incidence of 2–8/
100,000 in the United States and Europe (Manolio et
al. 1992). The application of molecular genetic tech-
niques has started to delineate the molecular bases of
these syndromes through the demonstration of altera-
tions of myocardial contractile and structural proteins,
such as the cardiac b-myosin heavy-chain (MYH7) gene,
which accounts for ∼75% of the familial cases of hy-
pertrophic cardiomyopathies (Geisterfer-Lowrance et al.
1990). There is growing evidence that mtDNA muta-
tions can cause cardiac disease, including cardiomyop-
athies and cardiac conduction block. In addition,
cardiomyopathy may result from bioenergetic defects
caused by mutations in nuclear-encoded subunits of the
respiratory chain or in nuclear genes controlling the in-
tegrity, replication, and expression of mtDNA (Corto-
passi et al. 1992; Kelly and Strauss 1994; DiMauro and
Bonilla 1997).
We report here a 35-year-old woman who was eval-
uated because of heart failure. At age 23–24 years, dur-
ing her first pregnancy, the patient noted easy fatigability,
shortness of breath, and palpitations. Chest x-ray re-
vealed cardiomegaly with prominent left-atrial enlarge-
ment. Cardiological evaluation suggested a restrictive
cardiomyopathy. Episodes of atrial fibrillation and flut-
ter required cardioversion on several occasions. Four
years later, her clinical condition worsened during a sec-
ond pregnancy. While in sinus rhythm, she was a New
York Heart Association class I-II patient but when in
atrial arrhythmia she worsened to class III. A clinical
and metabolic work-up for heart transplantation was
performed. Family history was remarkable for the
mother and maternal grandmother, who had both died
of unspecified heart diseases in their late 30s. A 25-year-
old brother had a childhood heart murmur but was free
of cardiac symptoms. The proposita’s two daughters are
asymptomatic at ages 11 and 7 years, but the older
daughter had had a cardiac murmur in infancy (fig. 1A).
At age 35 years, physical examination, including neu-
rological and otolaryngeal evaluations, showed a short
and thin woman without other symptoms and signs
commonly found in patients with mitochondrial en-
cephalomyopathy, including ptosis, external ophthal-
moparesis, pigmentary retinopathy, hearing loss, or
diabetes mellitus. A two-dimensional echocardiogram
revealed severe restrictive cardiomyopathy, with mod-
erate interventricular septum hypertrophy (1.3 mm;
normal !1.0 mm). An endomyocardial biopsy showed
normal myofibrillar array, minimal hypertrophy of
cardiomyocytes, and absence of inflammation. There
were no abnormal deposits of glycogen, iron, or amy-
loid. A diagnosis of idiopathic restrictive cardiomyopa-
thy was made.
After the subjects gave informed consent, we per-
formed our studies under our institutional review
board’s protocol. Skeletal muscle biopsy of the quad-
riceps did not reveal typical mitochondrial abnormali-
ties, such as ragged red fibers or cytochrome c oxidase
(COX)–negative fibers. The most prominent histochem-
ical abnormalities were central or paracentral minicores,
which were easily identified, in many muscle fibers, as
regions of decreased COX stain. Minicores were also
detected by light microscopy in NADH-stained skeletal
muscle sections (fig. 2). Electron microscopy revealed
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Figure 1 A, Pedigree of family harboring the A1555G mutation. Arrowhead indicates proband. B, Autoradiogram of the restriction-
length–polymorphism analysis used to quantitate mutant mtDNA. The normal 316-bp PCR-amplified fragment is cut by the endonuclease
Alw26I into two fragments (219 and 97 bp). The A1555G mutation abolishes the Alw26I site. Individuals are as shown in figure 1A. “CTRL”
is a normal control; wbc  white blood cells; skin1  cultured skin fibroblasts, first passage; skin2  cultured skin fibroblasts, second passage;
myo  cultured myoblasts; m  skeletal muscle.
foci of myofibers with prominent smearing of Z-lines
and absence of mitochondria. Biochemical studies in
muscle homogenate and skin fibroblasts showed slightly
decreased activities of multiple complexes of the respi-
ratory chain when values were normalized to activity of
citrate synthase, a mitochondrial matrix enzyme reflect-
ing total mitochondrial content. Specifically, the residual
activities of NADH-dehydrogenase and COXwere 50%
and 39%, respectively, of the mean values measured in
control muscles. PCR followed by SSCP and sequence
analyses of our proband’s muscle mtDNA identified one
possible pathogenic base change, an ArG transition at
nt 1555. By PCR, we amplified all 22 mtDNA-encoded
tRNA genes and did not identify any additional point
mutations by direct sequencing of both strands of the
PCR products. The A1555G mutation was hetero-
plasmic, accounting for 55% of total muscle mtDNA,
and similar proportions were detected in blood and pri-
mary skin fibroblasts cultures (57% and 60%, respec-
tively). Higher levels of mutated mtDNAs were found
in paraffin sections of an endomyocardial biopsy (89%).
The mutation was present in high percentages in blood
from the two daughters (95% in individual IV-1 and
50% in individual IV-2), the only tissues available for
study (fig. 1B). No additional maternal members of this
family were available for genetic testing.
When we examined the effects of the A1555G mu-
tation on the translational capacity of cultured skin fi-
broblasts in the presence or absence of aminoglycoside
(gentamicin, 0.5 mg/ml), we found moderate protein-
synthesis defects under both conditions. The relative la-
beling ratios and electrophoretic mobility of mitochon-
drial translation products in cell lines harboring 60%
mutated mtDNA did not differ significantly from those
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Figure 2 A, NADH-TR stain of the skeletal muscle biopsy. Arrows indicate minicores. B, Abundance of mutated mitochondrial genomes
in normal and abnormal (minicore) fibers, by single-muscle-fiber PCR analysis. The difference is statistically significant ( ).P ! .05
observed in controls in three independentmeasurements.
However, there was an overall decrease in the rate of
protein labeling, with an average decrease of 35%,
which became more apparent (40%) when aminogly-
coside was added at concentrations used routinely, in
animal cell cultures, to eliminate contaminating micro-
organisms (fig. 3).
Clinically, our patient suffered from a restrictive car-
diomyopathy from early adulthood, with a family his-
tory suggesting maternal transmission, whereas her
brother and one of her daughters had transient valvular
heart disease in early childhood. However, the daughters
remain at risk for cardiomyopathy, because cardiac
symptoms in our proposita did not start until she was
in her early 20s and worsened considerably over the
course of the next 10 years. Likewise, both her mother
and the maternal grandmother died suddenly in their
30s of cardiac failure. We have identified the A1555G
mutation, which we deem responsible for her symptoms,
on the basis of the following considerations. First, the
A1555G mutation was heteroplasmic, both in the pa-
tient and in her maternal relatives. Heteroplasmy, the
coexistence of wild-type and mutated mtDNAmolecules
in the same individual, is regarded as an indicator of
pathogenicity, and the abundance of mutated genomes
usually correlates with the severity of the phenotype.
Although this same base change has been associatedwith
either aminoglycoside-induced deafness (AID) or non-
syndromic hearing loss in several Asian, African, and
Middle Eastern pedigrees, usually in a homoplasmic
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Figure 3 Electrophoretic mobility of the mitochondrial trans-
lation products. Lane 1, III-1 skin fibroblasts (aminoglycoside minus).
Lane 2, III-2 skin fibroblasts (aminoglycoside plus). Lanes 3 and 4,
skin fibroblasts from normal controls. Lane 5, skin fibroblasts from a
disease control harboring a high percentage of the G8363A mtDNA
mutation (Family A, individual III-4, in Santorelli et al. 1996).
state (Prezant et al. 1993), there is evidence of pheno-
typic heterogeneity. Shoffner et al. (1996) have described
a Caucasian family harboring the A1555G mutation, in
association with both SNHL and Parkinson disease,with
onset in middle age. Complex I activity was decreased
in muscle samples of several members of that family, and
the degree of the biochemical defect correlated with the
severity of the clinical phenotype. It is possible that ad-
ditional phenotypes will be associated with this muta-
tion. Second, the clinical expression appears consistent
across three generations of this family, with variations
in age at onset and disease progression, possibly resulting
from differences in proportions and tissue distributions
of mutant genomes. Because the symptoms do not man-
ifest fully until adulthood, individuals IV-1 and IV-2 are
at high risk of developing cardiomyopathy. Third, we
noted a statistically significant correlation between the
abundance of mutated mtDNAs in single muscle fibers
and the presence of “minicores” in our proband (P !
; fig. 2). Whereas minicores and corelike formations.05
have been reported in other myopathies, including nem-
aline myopathy (Afifi et al. 1965) and limb-girdle
dystrophy (Engel et al. 1971), these structural alter-
ations usually are not found in mitochondrial ence-
phalomyopathies. Although the finding of minicores in
our proband’s skeletal muscle may be nonspecific, the
statistically significant association between their pres-
ence and the number of mutated genomes in single fibers
suggests a causal relationship. To the best of our knowl-
edge, no morphological studies in skeletal muscle of pa-
tients harboring the A1555G mutations have been re-
ported. It is also noteworthy that Fananapazir et al.
(1993) reported similar morphological changes in soleus
muscle biopsies taken from patients with hypertrophic
cardiomyopathy as a result of mutations in the MYH7
gene. In those cases, a simultaneousmitochondrial defect
was hypothesized but not examined at molecular genetic
or biochemical levels. Last, our data suggest that the
pathogenetic mechanism of the A1555G mutation in-
volves a primary mitochondrial translation defect, re-
sulting from the base change in the decoding site of the
small ribosome. Cells harboring the A1555G mutation
showed a decreased rate of mitochondrial protein syn-
thesis when compared with controls, even in the absence
of aminoglycoside in the culture medium. Decreased syn-
thesis of the subunits of respiratory complexes is likely
to impair ATP production, with deleterious effects on
cell functions and ultimately resulting in cell death. If
this occurs in cardiomyocytes, it could result in heart
failure, especially during periods of higher metabolic de-
mand, such as pregnancy, as in our patient.
An intriguing issue raised by our report regards the
phenotypic consequences of the A1555G mutation. Phe-
notypic heterogeneity is a common feature of diseases
associated with mtDNA defects and is thought to result
from differential tissue distribution of the mutated ge-
nomes. For example, the A3243G base change in the
tRNALeu(UUR) gene, although primarily associated with
mitochondrial myopathy, encephalopathy, lactic acido-
sis, and strokelike episodes (MELAS), is also responsible
for other syndromes, such as diabetes mellitus with deaf-
ness, progressive external ophthalmoparesis, and Leigh
syndrome (Shoffner and Wallace 1995). The A1555G
mutation had been long considered an exception to this
rule because it seemed to cause ototoxicity invariably
and exclusively, occurring either spontaneously or after
exposure to aminoglycosides. However, both this report
and the family described by Shoffner et al. (1996)
broaden the clinical spectrum for the A1555Gmutation.
The vulnerability of the auditory system has been at-
tributed to the fact that the mutation affects a 12S
rRNA–gene region that is homologous to the aminogly-
coside-binding site of the small rRNA in bacteria. More-
over, the mutation lies within a conserved domain that
in the Escherichia coli 6S rRNA gene forms an essential
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part of the decoding site of the ribosome. This region is
crucial for RNA-protein association, RNA-RNA inter-
action, or both; therefore, the mutation could enhance
sensitivity to aminoglycosides in the hairy cells of Corti’s
organ, through defective protein synthesis. Deafness is
not present in our family; however, restrictive cardio-
myopathy is the sole clinical feature, a finding never
before reported.
The fact that many patients with the A1555G mu-
tation have been asymptomatic prior to aminoglycoside
therapy suggests that the mutation alone is functionally
mild (Hutchin et al. 1993). Prezant et al. (1993) hy-
pothesized a “two-hit” model; the 12S rRNA mutation
apparently alters the aminoglycoside-binding site, thus
causing greater susceptibility to the toxic effects of the
drug. In addition, other genetic alterations, perhaps in
nDNA, modify the phenotypic expression of this
mtDNA mutation. Therefore, we cannot exclude the
possibility that, in addition to the abundant mutated
mtDNAs detected in the proband’s heart biopsy, a sec-
ond genetic “hit” may have caused the cardiomyopathy
in our pedigree with the A1555G mutation. By con-
trasting the properties of transmitochondrial cybrids
harboring different percentages of the A1555G muta-
tion from AID patients and from our cardiomyopathy
patient, we may be able to detect biochemical differ-
ences, which could be attributed to a second mtDNA
alteration. As an alternative, nuclear DNA factors—for
example, alterations of a nuclear DNA–encoded mi-
tochondrial ribosomal protein—could modify the phe-
notypic expression of the A1555G mutation.
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